Table 1.

Clinical characteristics by patient subgroups

Long-PFSMultiple RespondersdLong-Term SurvivorseControlf
(n = 73)(n = 21)(n = 43)(n = 710)
Characteristicsn (%)Pn (%)Pn (%)Pn (%)
Age at diagnosis, y
 Median590.30a560.04a590.58a62
 Range29–7739–7540–7724–80
Primary site
 Ovary58 (79)0.01b14 (67)0.17b31 (72)0.05b537 (76)
 Peritoneum9 (12)5 (24)8 (19)154 (22)
 Fallopian tube6 (8)2 (10)4 (9)19 (3)
FIGO stage
 IIIC62 (85)0.80b18 (86)0.81b34 (79)0.42b595 (84)
 IV11 (15)3 (14)9 (21)115 (16)
Residual diseaseg
 Nil0 (0)<0.001b2 (10)0.03b0 (0)0.006b146 (21)
 ≤1 cm35 (48)14 (67)18 (42)222 (31)
 >1 cm24 (33)4 (19)15 (35)197 (28)
 Size unknown12 (16)1 (5)9 (21)86 (12)
 Not resected2 (3)0 (0)1 (2)15 (2)
 Not known0 (0)0 (0)0 (0)44 (6)
Neoadjuvant therapy
 Yes1 (1)<0.001b3 (14)0.66b0 (0)0.002b128 (18)
 No72 (99)18 (86)43 (100)582k (82)
Primary platinum therapy
 Yes73 (100)0.16b21 (100)0.45b43 (100)0.28b691k (97)
 No0 (0)0 (0)0 (0)19 (3)
Primary treatment detailsh
 Platinum/taxane61 (84)0.06b18 (86)0.35b34 (79)0.35b561 (79)
 Platinum only4 (5)0 (0)3 (7)74 (10)
 Platinum/taxane/otheri4 (5)2 (10)4 (9)45 (6)
 Platinum/otherj4 (5)1 (5)2 (5)11k (2)
 No treatment0 (0)0 (0)0 (0)19 (3)
Current status
 Alive with no progression41 (56)<0.001b0 (0)0.44b29 (67)<0.001b28 (4)
 Alive with progression8 (11)0 (0)7 (16)24 (3)
 Dead24 (33)21 (100)7 (16)658 (93)
Progression-free survival from diagnosis (months)
 Median161.9<0.001c18.20.32cUndefined<0.001c11.9
 Range36.7–247.59.60–37.015.6–247.50–149.8
Overall survival from diagnosis (months)
 MedianUndefined<0.001c70.20.004cUndefined<0.001c33.1
 Range36.7–247.543.2–122.8120.8–247.50–268.6
>10 years overall survival from diagnosis40 (55)1 (5)43 (100)33 (5)
Overall grade
 10 (0)0.10b0 (0)0.56b0 (0)0.08b33 (6)
 213 (19)4 (22)13 (31)109 (20)
 357 (81)14 (78)29 (69)416 (75)
 Not known/neoadjuvantl331152
  • NOTE: Exceptional Responder patient subgroups were compared with unselected patients with advanced stage (stage IIIC/IV) serous ovarian cancer (control). Statistical comparisons were calculated as follows:

  • aMann–Whitney test.

  • bχ2 test.

  • cLog-rank test.

  • dIncludes one case that meets the criteria for Long-PFS, Multiple Responder and Long-Term Survivor.

  • eIncludes 40 cases that meet the criteria for Long-PFS and Long-Term Survivor.

  • fUnselected serous ovarian cancer cohort excluding cases that meet criteria for Long-PFS, Multiple Responder or Long-Term Survivor (n = 75).

  • gPatients who had residual disease after primary cytoreductive surgery but the size was not recorded were classified as “Size unknown,” and patients for whom it was not recorded whether or not they had residual disease were classified as “Not known.”

  • hIntraperitoneal chemotherapy received (number of patients indicated in brackets): Long-PFS (1), Multiple Responder (1), Control (6).

  • iOther chemotherapy received in addition to platinum/taxane: Long-PFS: gemcitabine (3), topetecan (1): Multiple Responder: gemcitabine (1), liposomal doxorubicin (1); Long-Term Survivor: gemcitabine (3), topetecan (1); Control: gemcitabine (18), liposomal doxorubicin (18), topetecan (6), bevacizumab (1), etoposide (1), and doxorubicin (1).

  • jOther chemotherapy received in addition to platinum: Long-PFS: gemcitabine (2), cyclophosphamide (1), not known (1): Multiple Responder: cyclophosphamide (1); Long-Term Survivor: cyclophosphamide (1), not known (1). Control: gemcitabine (4), topotecan (3), cyclophosphamide (1), not known (3).

  • kIncludes 3 patients where primary chemotherapy details are not known.

  • lPatients who received neoadjuvant chemotherapy or for whom grade was not known were excluded from overall grade analysis.